EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors

Jianming Diao, Zhigong Wei, Yiyan Pei, Junyou Ge, Yan Qing, Youneng Wei, Ye Chen, Xingchen Peng

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03885-1 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jianming Diao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center, West China Hospital & State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors, Nasopharyngeal Neoplasms, Lymphocyte Subsets. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaImmune Checkpoint InhibitorsNasopharyngeal NeoplasmsLymphocyte SubsetsB7-H1 AntigenNeoplasm Recurrence, LocalHumansFemaleMalePrognosisMiddle AgedAdultAgedNeoplasm Metastasis

Stichwörter der Autor:innen

Immune checkpoint inhibitorsLymphocyte subsetsNasopharyngeal carcinomaPD-L1 inhibitorPrognosis

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center, West China Hospital & State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.
  • Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 463527617@qq.com.
  • Department of Biotherapy, Cancer Center, West China Hospital & State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China. pxx2014@163.com.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Diao, J., Wei, Z., Pei, Y., Ge, J., Qing, Y., Wei, Y., Chen, Y., & Peng, X. (2025). Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03885-1

Vancouver

Diao J, Wei Z, Pei Y, Ge J, Qing Y, Wei Y, et al. Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03885-1

BibTeX
@article{Diao2025,
  author = {Diao, Jianming and Wei, Zhigong and Pei, Yiyan and Ge, Junyou and Qing, Yan and Wei, Youneng and Chen, Ye and Peng, Xingchen},
  title = {Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03885-1}
}
Kostenlos starten →